Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum

Michael J. Swartz, Michael A. Hughes, Deborah A. Frassica, Joseph Herman, Charles J. Yeo, Taylor S. Riall, Keith D. Lillemoe, John L. Cameron, Ross C. Donehower, Daniel A. Laheru, Ralph H. Hruban, Ross A. Abrams

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Hypothesis: Adjuvant chemoradiation improves local control and survival in patients with node-positive duodenal adenocarcinoma treated with pancreaticoduodenectomy. Design: A retrospective review of outcomes, with a planned comparison with historical controls. Setting: A single, high-volume academic referral center. Patients: All patients with periampullary carcinoma treated with pancreaticoduodenectomy and adjuvant chemoradiotherapy at The Johns Hopkins Hospital between 1994 and 2003. Fourteen cases of node-positive duodenal adenocarcinoma were identified. Median radiation dose was 5000 cGy (range, 4000-5760 cGy). Concurrent fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy. Results: The median follow-up was 12 months for patients who died and 42 months for those who lived. Death occurred in 7 of 14 patients (50%) during the follow-up period. Median survival for all patients was 41 months, and the 5-year survival rate was 44%. Of the 7 patients who experienced disease recurrence, 6 experienced distant metastasis as first recurrence. One of these 7 patients experienced both local recurrence and distant metastasis. Local control for all patients in the study was 93%, which compares favorably with local control reported in a series of patients treated with surgery alone (67%). Compared with historical controls treated with surgery alone, patients who received adjuvant chemoradiation therapy had an improved median survival (21 months vs 41 months, respectively). Overall 5-year survival, however, was not improved (44% vs 43%, respectively). Conclusion: Adjuvant chemoradiation therapy after pancreaticoduodenectomy for node-positive duodenal adenocarcinoma may improve local control and median survival but does not impact 5-year overall survival.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalArchives of Surgery
Volume142
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Duodenum
Adenocarcinoma
Pancreaticoduodenectomy
Survival
Recurrence
Adjuvant Chemoradiotherapy
Maintenance Chemotherapy
Neoplasm Metastasis
Fluorouracil
Radiotherapy
Referral and Consultation
Survival Rate
Radiation
Carcinoma
Drug Therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Swartz, M. J., Hughes, M. A., Frassica, D. A., Herman, J., Yeo, C. J., Riall, T. S., ... Abrams, R. A. (2007). Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Archives of Surgery, 142(3), 285-288. https://doi.org/10.1001/archsurg.142.3.285

Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. / Swartz, Michael J.; Hughes, Michael A.; Frassica, Deborah A.; Herman, Joseph; Yeo, Charles J.; Riall, Taylor S.; Lillemoe, Keith D.; Cameron, John L.; Donehower, Ross C.; Laheru, Daniel A.; Hruban, Ralph H.; Abrams, Ross A.

In: Archives of Surgery, Vol. 142, No. 3, 03.2007, p. 285-288.

Research output: Contribution to journalArticle

Swartz, MJ, Hughes, MA, Frassica, DA, Herman, J, Yeo, CJ, Riall, TS, Lillemoe, KD, Cameron, JL, Donehower, RC, Laheru, DA, Hruban, RH & Abrams, RA 2007, 'Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum', Archives of Surgery, vol. 142, no. 3, pp. 285-288. https://doi.org/10.1001/archsurg.142.3.285
Swartz MJ, Hughes MA, Frassica DA, Herman J, Yeo CJ, Riall TS et al. Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Archives of Surgery. 2007 Mar;142(3):285-288. https://doi.org/10.1001/archsurg.142.3.285
Swartz, Michael J. ; Hughes, Michael A. ; Frassica, Deborah A. ; Herman, Joseph ; Yeo, Charles J. ; Riall, Taylor S. ; Lillemoe, Keith D. ; Cameron, John L. ; Donehower, Ross C. ; Laheru, Daniel A. ; Hruban, Ralph H. ; Abrams, Ross A. / Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. In: Archives of Surgery. 2007 ; Vol. 142, No. 3. pp. 285-288.
@article{9037b8ff6e704ba588d72bfc58bcf25a,
title = "Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum",
abstract = "Hypothesis: Adjuvant chemoradiation improves local control and survival in patients with node-positive duodenal adenocarcinoma treated with pancreaticoduodenectomy. Design: A retrospective review of outcomes, with a planned comparison with historical controls. Setting: A single, high-volume academic referral center. Patients: All patients with periampullary carcinoma treated with pancreaticoduodenectomy and adjuvant chemoradiotherapy at The Johns Hopkins Hospital between 1994 and 2003. Fourteen cases of node-positive duodenal adenocarcinoma were identified. Median radiation dose was 5000 cGy (range, 4000-5760 cGy). Concurrent fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy. Results: The median follow-up was 12 months for patients who died and 42 months for those who lived. Death occurred in 7 of 14 patients (50{\%}) during the follow-up period. Median survival for all patients was 41 months, and the 5-year survival rate was 44{\%}. Of the 7 patients who experienced disease recurrence, 6 experienced distant metastasis as first recurrence. One of these 7 patients experienced both local recurrence and distant metastasis. Local control for all patients in the study was 93{\%}, which compares favorably with local control reported in a series of patients treated with surgery alone (67{\%}). Compared with historical controls treated with surgery alone, patients who received adjuvant chemoradiation therapy had an improved median survival (21 months vs 41 months, respectively). Overall 5-year survival, however, was not improved (44{\%} vs 43{\%}, respectively). Conclusion: Adjuvant chemoradiation therapy after pancreaticoduodenectomy for node-positive duodenal adenocarcinoma may improve local control and median survival but does not impact 5-year overall survival.",
author = "Swartz, {Michael J.} and Hughes, {Michael A.} and Frassica, {Deborah A.} and Joseph Herman and Yeo, {Charles J.} and Riall, {Taylor S.} and Lillemoe, {Keith D.} and Cameron, {John L.} and Donehower, {Ross C.} and Laheru, {Daniel A.} and Hruban, {Ralph H.} and Abrams, {Ross A.}",
year = "2007",
month = "3",
doi = "10.1001/archsurg.142.3.285",
language = "English (US)",
volume = "142",
pages = "285--288",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum

AU - Swartz, Michael J.

AU - Hughes, Michael A.

AU - Frassica, Deborah A.

AU - Herman, Joseph

AU - Yeo, Charles J.

AU - Riall, Taylor S.

AU - Lillemoe, Keith D.

AU - Cameron, John L.

AU - Donehower, Ross C.

AU - Laheru, Daniel A.

AU - Hruban, Ralph H.

AU - Abrams, Ross A.

PY - 2007/3

Y1 - 2007/3

N2 - Hypothesis: Adjuvant chemoradiation improves local control and survival in patients with node-positive duodenal adenocarcinoma treated with pancreaticoduodenectomy. Design: A retrospective review of outcomes, with a planned comparison with historical controls. Setting: A single, high-volume academic referral center. Patients: All patients with periampullary carcinoma treated with pancreaticoduodenectomy and adjuvant chemoradiotherapy at The Johns Hopkins Hospital between 1994 and 2003. Fourteen cases of node-positive duodenal adenocarcinoma were identified. Median radiation dose was 5000 cGy (range, 4000-5760 cGy). Concurrent fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy. Results: The median follow-up was 12 months for patients who died and 42 months for those who lived. Death occurred in 7 of 14 patients (50%) during the follow-up period. Median survival for all patients was 41 months, and the 5-year survival rate was 44%. Of the 7 patients who experienced disease recurrence, 6 experienced distant metastasis as first recurrence. One of these 7 patients experienced both local recurrence and distant metastasis. Local control for all patients in the study was 93%, which compares favorably with local control reported in a series of patients treated with surgery alone (67%). Compared with historical controls treated with surgery alone, patients who received adjuvant chemoradiation therapy had an improved median survival (21 months vs 41 months, respectively). Overall 5-year survival, however, was not improved (44% vs 43%, respectively). Conclusion: Adjuvant chemoradiation therapy after pancreaticoduodenectomy for node-positive duodenal adenocarcinoma may improve local control and median survival but does not impact 5-year overall survival.

AB - Hypothesis: Adjuvant chemoradiation improves local control and survival in patients with node-positive duodenal adenocarcinoma treated with pancreaticoduodenectomy. Design: A retrospective review of outcomes, with a planned comparison with historical controls. Setting: A single, high-volume academic referral center. Patients: All patients with periampullary carcinoma treated with pancreaticoduodenectomy and adjuvant chemoradiotherapy at The Johns Hopkins Hospital between 1994 and 2003. Fourteen cases of node-positive duodenal adenocarcinoma were identified. Median radiation dose was 5000 cGy (range, 4000-5760 cGy). Concurrent fluorouracil-based chemotherapy was given with radiation therapy, followed by maintenance chemotherapy. Results: The median follow-up was 12 months for patients who died and 42 months for those who lived. Death occurred in 7 of 14 patients (50%) during the follow-up period. Median survival for all patients was 41 months, and the 5-year survival rate was 44%. Of the 7 patients who experienced disease recurrence, 6 experienced distant metastasis as first recurrence. One of these 7 patients experienced both local recurrence and distant metastasis. Local control for all patients in the study was 93%, which compares favorably with local control reported in a series of patients treated with surgery alone (67%). Compared with historical controls treated with surgery alone, patients who received adjuvant chemoradiation therapy had an improved median survival (21 months vs 41 months, respectively). Overall 5-year survival, however, was not improved (44% vs 43%, respectively). Conclusion: Adjuvant chemoradiation therapy after pancreaticoduodenectomy for node-positive duodenal adenocarcinoma may improve local control and median survival but does not impact 5-year overall survival.

UR - http://www.scopus.com/inward/record.url?scp=33947394424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947394424&partnerID=8YFLogxK

U2 - 10.1001/archsurg.142.3.285

DO - 10.1001/archsurg.142.3.285

M3 - Article

VL - 142

SP - 285

EP - 288

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 3

ER -